Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Abcellera Biologics Inc (ABCL)

Abcellera Biologics Inc (ABCL)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,105,451
  • Shares Outstanding, K 281,581
  • Annual Sales, $ 233,155 K
  • Annual Income, $ 118,918 K
  • 60-Month Beta N/A
  • Price/Sales 18.07
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade ABCL with:

Options Overview Details

View History
  • Implied Volatility 74.91%
  • Historical Volatility 87.87%
  • IV Percentile 47%
  • IV Rank 20.48%
  • IV High 121.99% on 03/29/21
  • IV Low 62.78% on 11/19/21
  • Put/Call Vol Ratio 0.55
  • Today's Volume 638
  • Volume Avg (30-Day) 1,345
  • Put/Call OI Ratio 0.38
  • Today's Open Interest 50,117
  • Open Int (30-Day) 47,819

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/21
See More
  • Average Estimate 0.20
  • Number of Estimates 3
  • High Estimate 0.21
  • Low Estimate 0.19
  • Prior Year N/A
  • Growth Rate Est. (year over year) -99.98%

Price Performance

See More
Period Period Low Period High Performance
1-Month
13.18 +12.52%
on 11/10/21
17.93 -17.29%
on 11/03/21
-2.90 (-16.36%)
since 11/02/21
3-Month
13.18 +12.52%
on 11/10/21
22.63 -34.48%
on 09/17/21
-2.72 (-15.50%)
since 09/02/21

Most Recent Stories

More News
AbCellera Announces the Appointment of Neil Aubuchon as Chief Commercial Officer

AbCellera (Nasdaq: ABCL), a technology company with a centralized operating system for next-generation antibody discovery, announced today the appointment of Neil Aubuchon as Chief Commercial Officer...

ABCL : 14.83 (+1.71%)
AbCellera Reports Q3 2021 Business Results

AbCellera (Nasdaq: ABCL), a technology company with a centralized operating system for next-generation antibody discovery, today announced financial results for the third quarter of 2021. All financial...

ABCL : 14.83 (+1.71%)
How Much Upside is Left in AbCellera Biologics Inc. (ABCL)? Wall Street Analysts Think 161%

The consensus price target hints at a 160.5% upside potential for AbCellera Biologics Inc. (ABCL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings...

ABCL : 14.83 (+1.71%)
AbCellera Announces Virtual Presentations at Investor Conferences in November

AbCellera (Nasdaq: ABCL) today announced that executives from the Company will present at the following virtual investor conferences:

ABCL : 14.83 (+1.71%)
Lilly to Supply 614,000 Additional Doses of AbCellera-Discovered Bamlanivimab Together with Etesevimab to the U.S. Government for the Treatment or Post-Exposure Prevention of COVID-19

AbCellera (Nasdaq: ABCL) today announced an additional purchase by the U.S. government from Eli Lilly and Company (Lilly) for bamlanivimab with etesevimab for administration together. This neutralizing...

ABCL : 14.83 (+1.71%)
AbCellera to Report Third Quarter 2021 Financial Results on November 9, 2021

AbCellera (Nasdaq: ABCL) will announce its third quarter 2021 financial results on Tuesday, November 9, 2021, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the...

ABCL : 14.83 (+1.71%)
AbCellera and Everest Medicines Announce Multi-Target Collaboration to Advance New Antibody Therapies

AbCellera (Nasdaq: ABCL) and Everest Medicines Limited (HKEX 1952.HK, “Everest”) announced today that they have entered into a multi-year collaboration and license agreement to discover therapeutic...

ABCL : 14.83 (+1.71%)
Lilly to Supply the EU and EEA with up to 220,000 Doses of AbCellera-Discovered Bamlanivimab Together with Etesevimab for the Treatment of Confirmed COVID-19

AbCellera (Nasdaq: ABCL) today announced the European Commission (EC) and Eli Lilly and Company (Lilly) have entered into a Joint Procurement Agreement to supply up to 220,000 doses of bamlanivimab together...

ABCL : 14.83 (+1.71%)
Pre-Market Brief: U.S. Stocks Set to Open Slightly Lower

Morning Markets Dec S&P 500 futures this morning are slightly lower by -0.10%. Weakness in mining stocks is leading the overall market lower, with the price of iron ore falling to a 1-year low. Stock...

X : 22.38 (+0.18%)
TTWO : 161.38 (+0.64%)
FANG : 106.43 (+3.33%)
USNA : 100.00 (+1.00%)
ABCL : 14.83 (+1.71%)
ZI : 62.51 (+5.36%)
TUEM : 2.22 (+0.45%)
BLI : 20.45 (+4.07%)
Emergency Use Authorization of AbCellera-Discovered Bamlanivimab Administered with Etesevimab Expanded by the FDA to Include Post-Exposure Prophylaxis for the Prevention of COVID-19

AbCellera (Nasdaq: ABCL) today announced the U.S. Food and Drug Administration (FDA) has expanded the Emergency Use Authorization (EUA) for bamlanivimab (LY-CoV555) 700 mg administered with etesevimab...

ABCL : 14.83 (+1.71%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

AbCellera Biologics Inc. is a technology company which searches, decodes and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease. AbCellera Biologics Inc. is based in Vancouver, Canada.

See More

Key Turning Points

3rd Resistance Point 15.95
2nd Resistance Point 15.43
1st Resistance Point 15.13
Last Price 14.83
1st Support Level 14.31
2nd Support Level 13.79
3rd Support Level 13.49

See More

52-Week High 71.91
Fibonacci 61.8% 49.48
Fibonacci 50% 42.55
Fibonacci 38.2% 35.61
Last Price 14.83
52-Week Low 13.18

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar